Research Paper Volume 16, Issue 8 pp 7188—7216
Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer
Figure 4. (A) The expression level of these three candidate cell cycle-related DEGs in BC or four BC subtypes (Basal-like; HER2; Luminal-A; Luminal-B) and normal patients. (B) Correlations between TPX2/UBE2C/CCNE2 expression and tumor stage in BRCA patients. P<0.05 is considered as difference. (C, D) Immunohistochemistry detecting the protein level of TPX2 in various stages. *P < 0.05. Scar bar: 100 μm.